featured
Heterogeneity Derived From 18F-FDG PET/CT Predicts Immunotherapy Outcome for Patients With Metastatic Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Heterogeneity derived from 18 F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patients
Cancer Med 2022 Mar 11;[EPub Ahead of Print], Y Xie, C Liu, Y Zhao, C Gong, Y Li, S Hu, S Song, X Hu, Z Yang, B WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.